Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001983460 | SCV002271970 | likely benign | Fanconi anemia | 2024-02-05 | criteria provided, single submitter | clinical testing | |
Quest Diagnostics Nichols Institute San Juan Capistrano | RCV003478916 | SCV004218599 | uncertain significance | not provided | 2023-04-14 | criteria provided, single submitter | clinical testing | To the best of our knowledge, the variant has not been reported in the published literature. The frequency of this variant in the general population, 0.00023 (8/34586 chromosomes, http://gnomad.broadinstitute.org), is uninformative in assessment of its pathogenicity. Analysis of this variant using bioinformatics tools for the prediction of the effect of amino acid changes on protein structure and function yielded predictions that this variant is benign. Based on the available information, we are unable to determine the clinical significance of this variant. |
Ambry Genetics | RCV004976092 | SCV005583249 | uncertain significance | Inborn genetic diseases | 2024-11-25 | criteria provided, single submitter | clinical testing | The p.E1344G variant (also known as c.4031A>G), located in coding exon 41 of the FANCA gene, results from an A to G substitution at nucleotide position 4031. The glutamic acid at codon 1344 is replaced by glycine, an amino acid with similar properties. This amino acid position is conserved. In addition, this alteration is predicted to be tolerated by in silico analysis. Based on the available evidence, the clinical significance of this variant remains unclear. |
Fulgent Genetics, |
RCV005008368 | SCV005642562 | uncertain significance | Fanconi anemia complementation group A | 2024-02-16 | criteria provided, single submitter | clinical testing |